DX126-262 drug introduction
General Name: Recombinant Humanized Anti-Her2 Monoclonal Antibody -Tub114 Conjugate for Intravenous Injection
Components: DX126-262 is an ADC drug formed by recombinant humanized anti-Her2 monoclonal antibody DX-CHO9 (IgG1) conjugated with Tub114 through a cysteine thiol linkage. Average molecular ratio of Tub114 to the antibody (ADR) in DX126-262 is about 3.5-3.8.
Specification: 82mg/ bottle
Intended Use: DX126-262 will be administered once every three weeks on the first day (Q3W) of 21 days of a cycle. The first intravenous infusion lasts for 90 min ± 5 min. If the first infusion is well tolerated, subsequent infusions can last for 30 minutes.
Dosage: The dosage was calculated based on the weight. Dose to be determined.
Intended Indication: Patients with advanced Her2-positive solid tumor.